These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. Khambata-Ford S; Garrett CR; Meropol NJ; Basik M; Harbison CT; Wu S; Wong TW; Huang X; Takimoto CH; Godwin AK; Tan BR; Krishnamurthi SS; Burris HA; Poplin EA; Hidalgo M; Baselga J; Clark EA; Mauro DJ J Clin Oncol; 2007 Aug; 25(22):3230-7. PubMed ID: 17664471 [TBL] [Abstract][Full Text] [Related]
6. Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 Trial. Siu LL; Shapiro JD; Jonker DJ; Karapetis CS; Zalcberg JR; Simes J; Couture F; Moore MJ; Price TJ; Siddiqui J; Nott LM; Charpentier D; Liauw W; Sawyer MB; Jefford M; Magoski NM; Haydon A; Walters I; Ringash J; Tu D; O'Callaghan CJ J Clin Oncol; 2013 Jul; 31(19):2477-84. PubMed ID: 23690424 [TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting. Asseburg C; Frank M; Köhne CH; Hartmann JT; Griebsch I; Mohr A; Osowski U; Schulten J; Mittendorf T Clin Ther; 2011 Apr; 33(4):482-97. PubMed ID: 21635994 [TBL] [Abstract][Full Text] [Related]
8. EGFR fluorescence in situ hybridization pattern of chromosome 7 disomy predicts resistance to cetuximab in KRAS wild-type metastatic colorectal cancer patients. Li YH; Wang F; Shen L; Deng YM; Shao Q; Feng F; An X; Wang FH; Wang ZQ; Xu RH; Shao JY Clin Cancer Res; 2011 Jan; 17(2):382-90. PubMed ID: 20884623 [TBL] [Abstract][Full Text] [Related]
9. HPV16 infection of HaCaTs is dependent on β4 integrin, and α6 integrin processing. Aksoy P; Abban CY; Kiyashka E; Qiang W; Meneses PI Virology; 2014 Jan; 449():45-52. PubMed ID: 24418536 [TBL] [Abstract][Full Text] [Related]
10. Understanding the predictive role of K-ras for epidermal growth factor receptor-targeted therapies in colorectal cancer. Ramos FJ; Macarulla T; Capdevila J; Elez E; Tabernero J Clin Colorectal Cancer; 2008 Dec; 7 Suppl 2():S52-7. PubMed ID: 19064407 [TBL] [Abstract][Full Text] [Related]
11. Parathyroid hormone-related protein regulates integrin α6 and β4 levels via transcriptional and post-translational pathways. Bhatia V; Mula RV; Falzon M Exp Cell Res; 2013 Jun; 319(10):1419-30. PubMed ID: 23499737 [TBL] [Abstract][Full Text] [Related]
12. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. Zhang W; Gordon M; Schultheis AM; Yang DY; Nagashima F; Azuma M; Chang HM; Borucka E; Lurje G; Sherrod AE; Iqbal S; Groshen S; Lenz HJ J Clin Oncol; 2007 Aug; 25(24):3712-8. PubMed ID: 17704420 [TBL] [Abstract][Full Text] [Related]
13. Role of cetuximab and sorafenib in treatment of metastatic colorectal cancer. Galal KM; Khaled Z; Mourad AM Indian J Cancer; 2011; 48(1):47-54. PubMed ID: 21248446 [TBL] [Abstract][Full Text] [Related]
14. Ras mutational status is a biomarker for resistance to EGFR inhibitors in colorectal carcinoma. Dempke WC; Heinemann V Anticancer Res; 2010 Nov; 30(11):4673-7. PubMed ID: 21115922 [TBL] [Abstract][Full Text] [Related]
15. Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers. Rosa R; Melisi D; Damiano V; Bianco R; Garofalo S; Gelardi T; Agrawal S; Di Nicolantonio F; Scarpa A; Bardelli A; Tortora G Clin Cancer Res; 2011 Oct; 17(20):6531-41. PubMed ID: 21890455 [TBL] [Abstract][Full Text] [Related]
16. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Bertotti A; Migliardi G; Galimi F; Sassi F; Torti D; Isella C; Corà D; Di Nicolantonio F; Buscarino M; Petti C; Ribero D; Russolillo N; Muratore A; Massucco P; Pisacane A; Molinaro L; Valtorta E; Sartore-Bianchi A; Risio M; Capussotti L; Gambacorta M; Siena S; Medico E; Sapino A; Marsoni S; Comoglio PM; Bardelli A; Trusolino L Cancer Discov; 2011 Nov; 1(6):508-23. PubMed ID: 22586653 [TBL] [Abstract][Full Text] [Related]
17. Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. Ince WL; Jubb AM; Holden SN; Holmgren EB; Tobin P; Sridhar M; Hurwitz HI; Kabbinavar F; Novotny WF; Hillan KJ; Koeppen H J Natl Cancer Inst; 2005 Jul; 97(13):981-9. PubMed ID: 15998951 [TBL] [Abstract][Full Text] [Related]
18. Real-time imaging of integrin β4 dynamics using a reporter cell line generated by Crispr/Cas9 genome editing. Elaimy AL; Wang M; Sheel A; Brown CW; Walker MR; Amante JJ; Xue W; Chan A; Baer CE; Goel HL; Mercurio AM J Cell Sci; 2019 Jul; 132(15):. PubMed ID: 31262785 [TBL] [Abstract][Full Text] [Related]
19. UNC5C‑knockdown enhances the growth and metastasis of breast cancer cells by potentiating the integrin α6/β4 signaling pathway. Yuan M; Xie F; Xia X; Zhong K; Lian L; Zhang S; Yuan L; Ye J Int J Oncol; 2020 Jan; 56(1):139-150. PubMed ID: 31789389 [TBL] [Abstract][Full Text] [Related]
20. α6β4 Integrin Genetic Variations (A380T and R1281W) and Breast Cancer Risk in an Argentinian Population. Acosta KB; Lorenzini Campos MN; Etcheverry SB; Zapata PD Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27763564 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]